The diagnosis of viral causes of many infectious diseases is difficult due to the inherent sequence diversity of viruses as well as the ongoing emergence of novel viral pathogens, such as SARS coronavirus and 2009 pandemic H1N1 influenza virus, that are not detectable by traditional methods. To address these challenges, we have previously developed and validated a pan-viral microarray platform called the Virochip with the capacity to detect all known viruses as well as novel variants on the basis of conserved sequence homology 1
1
. Using the Virochip, we have identified the full spectrum of viruses associated with respiratory infections, including cases of unexplained critical illness in hospitalized patients, with a sensitivity equivalent to or superior to conventional clinical testing [2] [3] [4] [5] . The Virochip has also been used to identify novel viruses, including the SARS coronavirus 6, 7 , a novel rhinovirus clade 5 , XMRV (a retrovirus linked to prostate cancer) 8 , avian bornavirus (the cause of a wasting disease in parrots) 9 , and a novel cardiovirus in children with respiratory and diarrheal illness 10 . The current version of the Virochip has been ported to an Agilent microarray platform and consists of ~36,000 probes derived from over ~1,500 viruses in GenBank as of December of 2009. Here we demonstrate the steps involved in processing a Virochip assay from start to finish (~24 hour turnaround time), including sample nucleic acid extraction, PCR amplification using random primers, fluorescent dye incorporation, and microarray hybridization, scanning, and analysis.
Video Link
The video component of this article can be found at http://www.jove.com/video/2536/
Protocol
The steps of the Virochip assay include (1) nucleic acid extraction from clinical samples, (2) reverse transcription of extracted RNA and 2 nd -strand cDNA synthesis, (3) PCR amplification of randomly primed cDNA, (3) Cy3 fluorescent dye incorporation, (4) hybridization of labeled material to the Virochip microarray, and (5) scanning and analysis (Figure 1) . The protocol shown below will demonstrate the use of the Virochip assay on a nasal swab sample from a child with an influenza-like illness.
Primer Sequences
Primer A 5'-GTTTCCCAGTCACGATA-(N 9 )-3' Primer B 5'-GTTTCCCAGTCACGATA-3'
Nucleic Acid Extraction
1. Nucleic acid extraction from clinical samples should be performed under Biosafety Level 2 (BSL-2) or higher conditions, as these samples are potentially infectious. 2. The nasal swab sample is transported in viral holding medium. Aliquot 200 μL of the sample into a 1.5 mL Eppendorf microcentrifuge tube. 3. Optional: pass sample through a 0.22 μm filter (to purify for viral particles) 4. Optional: pretreat sample with DNAse (to degrade host genomic DNA and purify for protected, encapsidated viral nucleic acid) using the Turbo DNAse kit (Ambion) per the manufacturer's instructions 5. Extract the sample using the Zymo ZR Viral RNA Extraction Kit or Qiagen Ultrasens Virus Kit per the manufacturer's instructions.
Reverse Transcription and 2
nd -strand CDNA Synthesis ("Round A")
